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Directed evolution, artificial selection toward de-
signed objectives, is routinely used to develop new 
molecular tools and therapeutics. Successful 
directed molecular evolution campaigns repeatedly 
test diverse sequences with a designed selective 
pressure. Unicellular organisms and their viral patho-
gens are exceptional for this purpose and have been 
used for decades. However, many desirable targets 
of directed evolution perform poorly or unnaturally 
in unicellular backgrounds. Here, we present a sys-
tem for facile directed evolution in mammalian cells. 
Using the RNA alphavirus Sindbis as a vector for 
heredity and diversity, we achieved 24-h selection 
cycles surpassing 103 mutations per base. Selec-
tion is achieved through genetically actuated se-
quences internal to the host cell, thus the system’s 
name: viral evolution of genetically actuating se-
quences, or ‘‘VEGAS.’’ Using VEGAS, we evolve tran-
scription factors, GPCRs, and allosteric nanobodies 
toward functional signaling endpoints each in less 
than 1 weeks’ time.
INTRODUCTION
Spontaneous genetic mutations diversify traits among a popula-
tion of organisms while selective pressure culls diverse popula-
tions. This enrichment of ultimately advantageous traits is a 
process known as evolution by means of natural selection (Dar-
win and Bynum, 2009; Wallace, 1855, 1871). Humans can accel-
erate the development of organisms with desirable traits by 
guiding evolution through artificial selection. This technique 
can be traced back to the earliest agricultural crops (Diamond, 
2002; Wright et al., 2005) and domesticated animals (Driscoll 
et al., 2009). As a biomedical laboratory tool, artificial selection 
has been instrumental in understanding myriad processes 
ranging from the cell cycle (Hartwell et al., 1970) to bacterial anti-
biotic resistance (Albert et al., 2005; Baym et al., 2016; Toprak 
et al., 2011). Artificial selection of targeted DNA sequences,rather thanwhole organisms, is called directed evolution (Arnold,
1998; Chen and Arnold, 1993). Directed evolution has been used
to create novel binding proteins (Hanes and Plückthun, 1997;
Xu et al., 2002), enzymes (Chen and Arnold, 1993; Kuchner
and Arnold, 1997), chemogenetic tools (Armbruster et al.,
2007), and fluorescent reporters (Campbell et al., 2002; Crameri
et al., 1996) with broad scientific and industrial utility.
Directed evolution approaches typically use peptide display or
microorganisms to screen large-scale DNA libraries that encode
mutant proteins. ‘‘Hits’’ from these systems are isolated, muta-
genized, and rescreened in an interrupted or iterative fashion.
Iterative systems minimize evolution cycle time and omit user-
biased ‘‘winner’’ selection by combining mutagenesis, selection,
and heredity in parallel. Iterative systems have been improved
using uninterrupted facile (McMahon et al., 2018) and continuous
methods (Badran and Liu, 2015; Carlson et al., 2014; Esvelt et al.,
2011). Although both methods have produced excellent results,
these systems have been developed outside the context of the
mammalian cell signaling environment. Consequently, incom-
patibility of function when transferring evolved products from
unicellular to mammalian systems frequently occurs (see
Armbruster et al., 2007 for examples), wherein additional rounds
of selection and focused mutagenesis must be performed. Addi-
tionally, the currently available directed evolution systems omit
classes of proteins that are usually incompatible with non-
mammalian host systems—including G-protein coupled recep-
tors (GPCRs).
GPCRs comprise one of the largest protein families in the hu-
man genome with >900 unique protein coding genes (Fredriks-
son et al., 2003; Wacker et al., 2017a). GPCRs represent the
largest class of druggable targets and are known to regulate
most biological processes (Hauser et al., 2017). Despite their
importance, GPCRs are largely omitted from directed evolution
studies due to their functional incompatibilities with non-
mammalian systems (although, see Armbruster et al., 2007;
Sarkar et al., 2008; Schütz et al., 2016). GPCRs are seven-trans-
membrane receptors that transduce extracellular signals into
biological responses via heterotrimeric G proteins and b-arrest-
ins (Gilman, 1987; Pierce et al., 2002). GPCR signal transduction
is accomplished via a network of interacting molecular switches
(Wacker et al., 2017a), yielding an isomerizing landscape of
conformations that evoke unique cellular signaling cascades
(De Lean et al., 1980; Kobilka and Deupi, 2007; Onaran and
Costa, 2009). GPCR-directed pharmaceuticals stabilize subsets
of this signaling landscape leading to stabilization of active (e.g.,
agonism) or inactive (Neubig et al., 2003; Wacker et al., 2017a)
states. A directed evolution system capable of targeting these
states, and the signaling pathways downstream of such targets,
could provide key insights necessary to advance cell signaling
biology and drug development.
Here, we present a system for the viral evolution of genetically
actuating sequences, which we dub ‘‘VEGAS,’’ using a facile
directed evolution platform in mammalian cells. Using the RNA
alphavirus Sindbis for parallel mutagenesis, selection, and he-
redity, we demonstrate the robust, directed, and functional
evolution of both GPCRs and allosteric GPCR intrabodies in
mammalian cell culture in less than 1 week.
RESULTS
Sindbis Virus for Directed Evolution in Mammalian Cell
Culture
Mammalian cell-based directed evolution has had many suc-
cesses (Armbruster et al., 2007; Berman et al., 2018; Buchholz
et al., 1998; Chan et al., 2017; Hess et al., 2016; Maheshri et al.,
2006), albeit using time consuming, costly, and specialized
screening platforms. The use of engineered viruses has advanced
the field (Berman et al., 2018), serving as vectors for library stor-
age, delivery, and heredity; the use of viruses, however, has
been limited to conventional iterative systems involving panning,
‘‘winner-picking,’’ and ex vivo mutagenesis. Such iterative
directed evolution approaches sabotage the powerful evolu-
tionary principles at play in competitive genetic populations
(Huston, 1979). Here, we aimed to develop a mammalian directed
evolution systemwhere viral mutagenesis, selection, and heredity
could operate simultaneously.
We required a mutagenic virus that could replicate freely at
titers sufficient for constant reinfection of naive cells in culture,
and for this, we focused on obligate RNA viruses, themostmuta-
genic viral class (Drake and Holland, 1999). Due to concerns
related to laboratory safety and utility only a handful of RNA vi-
ruses are feasible for routine use. Of those available, we focused
our efforts on the Alphavirus Sindbis, from the Togaviridae family
(Strauss et al., 1984; Xiong et al., 1989). Sindbis virus is a single-
stranded RNA virus encoding an RNA-dependent RNA replicase
targeted to the viral genome by cis-acting, conserved 5-30 se-
quences (Frolov et al., 2001). These sequences are required to
initiate replication and RNA templates, even those from related
viral families, cannot be replicated by the Sindbis virus replicase,
resulting in high selectivity between the replicase and the Sindbis
virus genome (Frolov et al., 2001), which functions simulta-
neously as a replication template and coding strand for viral
protein translation. Sindbis virus has been engineered as a trans-
gene delivery vector (Agapov et al., 1998; Schlesinger, 1993;
Strauss and Strauss, 1994; Xiong et al., 1989); here, we further
engineered Sindbis virus to control the packaging process using
mammalian expression vectors.
Wefirstdetermined thatSindbis viruscanbecontinuouslypack-
aged in mammalian cell culture using an expression plasmid en-
coding the Sindbis virus structural genome (Figure 1A, also referto Data S1 [VEGASSupplemental Resource] and Data S2 [VEGAS
ExtendedProtocol] for additional details). TransgenicSindbis virus
plasmid harboring green fluorescent protein (pTSin-EGFP) (STAR
Methods) was packaged and titered at 5.453 1011 genomes/mL
(Figure 1B) as determined by qRT-PCR targeting the Sindbis
virus packaging signal sequence (STAR Methods). This initial
titer was applied to 1 3 107 cells transfected with pCMV-
SSG (Sindbis structural genome) (STAR Methods) at an MOI
(multiplicity of infection) of 1. Harvesting and subsequent analysis
of the culture media from these cells revealed high viral titer pro-
duction, with 6.64 3 108 genomes/mL produced after 4 h and
5.57 3 1010 genomes/mL produced after 24 h (Figure 1B). The
24hsample fromround1was transferred tonaivecells transfected
with or without pCMV-SSG at an MOI = 1. After 24 h, pCMV-SSG
transfectedcellsproduced6.373108genomes/mLwhile untrans-
fected control cells produced 2.63 105 genomes/mL (Figure 1B).
Fluorescent imaging of the infected culture over time confirmed
passage of the EGFP transgene (Figure S1A). Transgene expres-
sion is rapid, with EGFP detectable in as few as 4 h post infection.
These experiments demonstrate that Sindbis virus can be used
for sustained transgene packaging in mammalian cell culture
using a plasmid-borne structural genome.
RNA viruses, such as Sindbis, are highly mutagenic, with no
known proof-reading capability. Approximations of RNA virus
mutation rates range from 105 to 103 mutations per base repli-
cated (Drake et al., 1998; Morley and Turner, 2017; Sanjuán
et al., 2010; Schnell et al., 1996; Strauss and Strauss, 1994).
As no prior study quantified the genetic stability of a non-essen-
tial transgenic gene during Sindbis virus replication, we next
determined themutation frequency of our directed evolution sys-
tem.We initiated packaging of pTSin-EGFP in pCMV-SSG trans-
fected cells and collected supernatant after 3, 6, 12, 24, and 36 h.
The EGFP transgenic segment, as well as the vector template
and initially packaged RNA, was amplified and sequenced using
an Illumina NextSeq500. The sequences were aligned (STAR
Methods) and quantified for positional sequence integrity of
EGFP (Figures S1B and S1C). A significant (p < 0.0001) (STAR
Methods) time-dependent increase in average mutation fre-
quency was observed when comparing the 0HR (initial RNA)
sample versus the 6, 12, 24, and 36 h samples (Figure 1C). The
number of observed insertions and deletions also increased
with time (Figure S1D). Nucleotide substitution rates were rela-
tively even, with the exception of a modest (p < 0.05) C > G pref-
erence in samples 6–36 h (Figure 1D), and events occured pro-
portionally across read lengths (Figures S1E–S1G). Linear
regression analysis ofmutation frequency versus time (Figure 1E)
yielded an estimate of 1.0 3 104 ± 3.7 3 105 mutations
base1/h—1 mutation per 1,000 bases replicated or >109 total
mutations per day at the observed viral production rates. This
high mutation rate, coupled to accumulating insertions and dele-
tions infrequently accessible to rational design platforms, makes
Sindbis virus an ideal candidate for developing a mammalian-
directed evolution platform.
Directed Evolution of Transcription Factors with
Sindbis Virus
To yield a robust directed evolution platform that leverages the




Figure 1. Sindbis Virus for Facile Directed Evolution in Mammalian Cell Culture
Development of Sindbis virus for facile, mutagenic viral propagation in mammalian cell culture.
(A) Design of plasmids used for facile directed evolutionwith Sindbis virus. Artificial Sindbis genome; Girdwood, MF459683.1. pSSGplasmid; capsid, E3, E2, E1, and
30 UTR moved to a mammalian expression vector. pTSin plasmid; the structural genome elements of the artificial Sindbis genome replaced by any transgene
sequence (pTSin). Propagation and selection can then be performed in mammalian cell culture using pTSin packaged virus applied to cells transfected with pSSG.
(B) qRT-PCR quantification of Sindbis virus production from cell culture. Data are represented as mean of individual biological replicates, N > 3.
(C) Mutations observed from Illumina paired-end sequencing of Sindbis packaged EGFP transgene over time. Mutation frequency is plotted as mutations
observed per read at each nucleotide position across the transgene. Data are plotted for each individual replicate (N = 3; 24HR and VECTOR, N = 2) around
mean ± 95% confidence interval.
(D) Base changes observed from sequencing of Sindbis packaged EGFP transgene over time. A, adenine, T, thymine, G, guanine, C, cytosine. Statistical
comparison tested within base groups between each time point.
(E) Calculation of Sindbis mutation rate from sequencing of Sindbis packaged EGFP transgene over time. Data are represented as mean ± SEM and as linear
regression, dotted line highlights the 99% confidence interval band.
See also Figure S1 and Data S1 and S2.
selective pressure must be applied. Each Sindbis viral particle
requires 240 copies of each of the structural proteins E1, E2,
and capsid to form a functional viral particle that can mature
and propagate (Tang et al., 2011), and without this envelope,
the virus is unable to mature and propagate. By engineering re-
strictions on structural genome transcription, we developed a
system to apply selective pressure on transgenic Sindbis virus.
As proof of concept for this method, we placed the Sindbis
virus structural genome under control of the tetracycline oper-
ator sequence (pTETO7-SSG) (Das et al., 2004; Gossen et al.,
1995; Orth et al., 2000; STAR Methods) and packaged trans-
genic Sindbis virus with tetracycline transactivator (pTSin-tTA)
(Gossen and Bujard, 1992; STAR Methods). We infected
cells ± TETO7-SSG with viral pTSin-tTA or pTSin-EGFP and
then treated cells with either the tTA inhibitor doxycycline
(DOX, 1 mM) or vehicle at the time of infection. Virus was pack-
aged at 3.53 3 1010 genomes/mL in the vehicle + TETO7-SSG
cell line, while <106 genomes/mL were detected for all other
conditions (Figure S2A).
Using the TS-tTA system, we sought to benchmark the capa-
bilities of VEGAS by evolving tTA to be DOX-insensitive. To
accomplish this, we packaged TS-tTA virus under non-selec-
tive conditions (R0) and exposed it to constant rounds of
selection using increasing concentrations of DOX (Figure 2A).
Seven selection rounds, encompassing just 7 days of evolution,
produced a large number of full-length tTA sequences (see
Table S1). By round 6, a consensus sequence dominated the
observed coding sequence pool that was carried through to
round 7. This consensus sequence, dubbed ‘‘R7,’’ was
completely resistant to DOX (Figure 2B). R7 possessed
twenty-two coding mutations spanning all functional domains
of the protein (Figure 2C). We had predicted that mutations
directly involved in ligand interaction (Figures 2C and 2D; Kisker
et al., 1995; Orth et al., 1999a, 1999b) would be enriched in the
final consensus. To our surprise, none of these residues were
mutated in R7. Instead, mutations accumulated primarily adja-
cent to key interacting residues for each functional domain
(Figures 2C and S2B), many of which have been previously
identified to reduce the effect of DOX on TETR-TETO interac-
tion (Berens et al., 1992; Hecht et al., 1993; Müller et al.,
1995; Orth et al., 1998; Scholz et al., 2004; Schubert et al.,
2001; Smith and Bertrand, 1988; Urlinger et al., 2000; Wiss-
mann et al., 1991; see Figure 2C and Table S2 for details). In
addition, a cluster of negatively charged residues comprising
helices 8 and 9 residing over the ligand binding pocket
spanning Q149-H179 (Figure 2D) were converted to primarily
positively charged residues (Figure 2C; Table S2). Among vary-
ing bacterial species, the net charge, but not specific residues,
of this loop is conserved, and this conserved charge landscape
has been proposed to attract the tetracycline-Mg2+ inducer
to the ligand binding pocket (Orth et al., 1998). The mutations
observed in R7 increase the net charge of this loop by +3.19,
concentrated near the ligand entry tunnel. This gain in local
charge presumably repels the positively charged DOX-Mg2+.
Interestingly, in addition to augmenting the peptide sequence
through directed evolution, our analysis of the nucleotide se-
quences from each round revealed codon usage optimizations
as well (Figures S2C and S2D). Non-synonymous mutationsacquired through tTA evolution converted rarely used codon se-
quences for BHK21, derived from Mesocricetus auratus, to the
more frequently used GAC (D, +13%), GAG (E, +29%), AAG
(K, +43%), TTG (L, 30%), and CAG (Q, +19%).
Augmenting TETR ligand sensitivity has been attempted previ-
ously using mammalian-directed evolution (Das et al., 2004),
wherein 2 mutations were identified in 114 days. Our evolution
of tTA generated an order of magnitude more functional muta-
tions in 7 days thereby illustrating how our Sindbis virus system
can be used for successful directed evolution of a transcription
factor in mammalian cell culture. Key to the evolutionary compo-
nent of this method is the actuation of a genetically encoded cir-
cuit to unlock expression of the Sindbis structural proteins,
capsid, E1, and E2. Consequently, we have named this Sindbis
virus system viral evolution of genetically actuating sequences,
or ‘‘VEGAS.’’
VEGAS for the Evolution of GPCRs
With VEGAS in hand to perform directed evolution in mammalian
cells, we focused our efforts on GPCRs, a superfamily of trans-
membrane receptors with substantial pharmacological and
physiological importance (Hauser et al., 2017; Wacker et al.,
2017a). Critical to the GPCR field is the mapping of interacting
residues associated with the transition from an inactive to active
receptor. Mapping these motifs can provide anchor points for
homology modeling, evolutionary sequence analysis, and ligand
design (Fan et al., 2009; Michino et al., 2015; Roth et al., 2017).
Even among the best studied receptors, using extensive muta-
tion campaigns and high resolution crystal structures of inactive
and active receptor conformations, the field has struggled to
consistently identify key residues involved in state transition
(Dror et al., 2011; Huang et al., 2015a; Latorraca et al., 2017).
Class A GPCRs possess conserved binding pockets and trigger
motif residues involved in the inactive to active state transition.
However, many class A GPCRs lack conservation within these
motifs, a disproportionate number of which are classified as
understudied or orphan receptors (Figure S3A). Here, we used
VEGAS to identify previously unknown constitutively active mu-
tations for the understudied receptor MRGPRX2; our approach
demonstrates how VEGAS can illuminate the complex confor-
mational changes involved in GPCR activation even in the
absence of structural information.
MRGPRX2 is a primate-exclusive GPCR recently identified
as an atypical opioid-recognition receptor (Lansu et al., 2017).
MRGPRX2 possesses limited homology to other opiate recep-
tors (see Table S3) and minimal conservation of classic
interacting residues. The curious composition of MRGPRX2
hampers de novo prediction of functional motifs. We therefore
used VEGAS to develop constitutively active mutations (CAMs)
of MRGPRX2. As VEGAS requires an activity-coupled tran-
scriptional response to gate selection, we screened MRGPRX2
activated by (+)-morphine, across a panel of transcription
factor reporters driving luciferase (luc2P, FLuc) expression
(Figure S3B). The serum response element (SRE) and serum
response factor (SRF) minimal promoters gave 5-fold re-
sponses 4 h post-ligand addition and persisted for 24 h. We
chose SRE for its lower total basal signal in unstimulated con-
ditions and replaced luc2P with the Sindbis virus structural
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Figure 2. Directed Evolution of Transcription Factors with Sindbis
Sindbis was used as a directed evolution platform to generate a doxycycline (DOX)-resistant variant of the transcription factor tTA.
(A) Nucleotide sequence alignment of TETR clones isolated from each round of selection to the wild type TETR(B) sequence. Each round is outlined in yellow or
blue, applied concentration of DOX to the left, name of individual clones to the right. Gray DOX values indicate no clones were isolated from the round. Red lines in
the alignment denote a sequence mismatch from wild type.
(B) TETO7-Rluc reporter assay with increasing concentrations of DOX. Dotted lines are selection round DOX concentrations, for reference. Data are represented
as mean ± SEM of individual biological replicates.
(C) Peptide sequence alignment of TETR(B) and the R7 consensus. Matching residues are shaded, mutations are unshaded. Alpha helices (a) are labeled and
color coded to match with palettes in (D) and S2B. Exact residue (D), position (@), or subtype (D) substitutions previously published to enhance tTA activity in the
presence of DOX as per Table S2. Residues (*) with direct involvement in DNA binding (green), ligand binding (magenta), and ligand entry (cyan) as per Orth et al.
(2000) and Schubert et al. (2004).
(D) Crystal structure PDB: 4AC0 of TETR(B) in complex with minocycline-Mg2+. Helix 8-9 ligand enclosure spanning Q149-H179 is displayed with spheres
highlighting the residues for mutations Q149R, Q152R, K155R, R158G, T160A (no density), D178G, and H197R observed in R7.
See also Figure S2, Tables S1 and S2, and Data S1 and S2.genome (SRE-SSG). Cells transfected with SRE-SSG were in-
fected with transgenic Sindbis virus harboring MRGPRX2 
(pTSin-MRGPRX2) and selected with diminishing amounts of 
(+)-morphine over 3 days (Figure 3). Resultant viral genomes 
were isolated, and their MRGPRX2 transgenes were tested in 
subsequent assays.
We presumed these clones would be CAMs, however, none of 
the isolated mutants mapped to classic sites of constitutive ac-
tivity modulation identified in other GPCRs (Figure S3C).We screened each mutant for activity in SRE-luc2P (Figure 3A),
b-arrestin recruitment (Figure 3B), and phosphoinositide (PI) hy-
drolysis (Figure 3C) functional assays.We also quantified surface
receptor expression via ELISA to ensure proper trafficking and
expression (Figure S3D). For SRE and TANGO assays, basal
activity across the variants increased at each evolutionary gener-
ation. TANGO basal activity reached 100% of wild type
(+)-morphine stimulation for three independent mutants:






Figure 3. VEGAS for the Evolution of GPCRs
Using VEGAS multiple constitutively active mutants of the GPCR MRGPRX2 were produced in 3 days through application of decreasing concentrations of the
MRGPRX2 agonist (+)-morphine. Mutations acquired in each round were tested functionally. Mutations are listed with their receptor residue position and
Ballesteros-Weinstein annotation.
(A) Serum response element (SRE) reporter assay. FLuc production equates to relative receptor activation. ND, no drug. Data are represented as mean ± SEM,
N = 3.
(B) TANGO reporter assay. RLuc production equates to receptor-mediated b-arrestin2 activation. ND, no drug. Data are represented as mean ± SEM, N = 3.
(C) Phosphoinositide hydrolysis assay. Accumulation of [3H] inositol equates to receptor-mediated Gaq activation. ND, no drug. Data are represented as
mean ± SEM, N = 3.
See also Figure S3, Table S3, and Data S1 and S2.
a proxy for Gaq activity, detected decreased basal activity, 
ligand potency, and efficacy for all mutants. Decreases in 
maximum agonist-induced Gaq activity correlated with in-
creases in constitutive TANGO and SRE activity.
VEGAS for the Evolution of Active-State Nanobodies 
GPCR ligands stabilize signal-state-specific receptor conforma-
tions (Kobilka and Deupi, 2007; Onaran and Costa, 2009; Stra-
chan et al., 2014), and the development of novel ligands is 
enhanced by signal-state-specific GPCR crystal structures 
(Che et al., 2018; Manglik et al., 2016; Wang et al., 2017). Nano-
bodies, genetically encodable antigen recognition domains from 
dromedaries (Muyldermans et al., 2001), can be used to obtain 
these stabilized active state structures (Che et al., 2018; Manglik 
et al., 2016; Rasmussen et al., 2007; Staus et al., 2016). The 
nanobodies developed in these studies mimic the Ga protein, 
displacing it. More desirable would be a nanobody that stabilizes 
the complex between GPCR and its transducer Ga protein. 
These nanobodies would be allosteric modulators capable of 
enhancing GPCR-Ga coupling. Using VEGAS, we can create 
allosteric nanobodies for multiple GPCR-Ga pairings in less 
than a week.
To create GPCR nanobodies using VEGAS, we first generated 
a GPCR-targeted nanobody library by immunizing a llama 
against the serotonin 2A (5-HT2A) GPCR bound to the high-affin-
ity agonist lysergic acid diethylamide (LSD). We isolated single-
domain antibodies from the peripheral blood mononuclear cells 
of the immunized llama through amplification of the variable re-
gion ‘‘VHH’’ of IgG (Pardon et al., 2014; STAR Methods). The 
VHH amplicon was used to generate a cDNA library of 1 3 
107 colonies, which was subsequently packaged in Sindbis vi-
rus. This library was then used to evolve intracellular targeting 
nanobodies against 5-HT2A, as well as the dopamine-D2 
(DRD2) and pH-sensing GPR68 (Huang et al., 2015b) receptors. 
Each of these receptors couples canonically to a different Ga 
protein (2A, Gaq; D2, Gai, 68, Gas). Developing nanobodies to-
ward each receptor serves to demonstrate the broad applica-
bility of the VEGAS system.
To evolve active state-stabilizing nanobodies for each GPCR, 
we first screened each receptor for transcription factor coupling 
(Figures S4A–S4F). All three receptors were determined to acti-
vate SRE with varying efficacy and we therefore chose to 
develop nanobodies that engage the SRE-signaling state for 
each receptor. Cells transfected with SRE-SSG and a GPCR 
were infected with an MOI = 1 of the viral nanobody library. To 
select for SRE activating nanobodies, 5-HT2A and DRD2 cultures 
were incubated in the absence of ligand, while GPR68 was incu-
bated at its inactive pH 8 (Huang et al., 2015b). Day 1 viral parti-
cles were harvested, the selection was repeated, and individual 
nanobody clones were isolated from the day 1 and 2 titers and 
sequenced. Clones with N R 2 identity in the subcloned popula-
tion were selected and screened for GPCR-dependent SRE acti-
vation (Figure 4B). Each evolution series produced nanobodies 
capable of SRE activation only in the presence of the intended 
GPCR target, with the exception of VGS-Nb1 that appears to 
constitutively activate SRE even under GPCR-free conditions. 
To determine if the nanobodies obtained using VEGAS came 
directly from the originating library, or were evolved, we deep-sequenced the clonal library using a NextSeq500 (STAR
Methods). Stringent end-to-end alignment of the entire
sequence pool (total reads equaled 20 million) was assessed
over 3 independent score cut-offs. Reads aligning to the
VEGAS-derived nanobodies are displayed in Figure 4A. Each
VEGAS-derived nanobody possessed sequences that were not
detected within or outside the complementarity-determining re-
gions (CDRs). In addition, we compared reference nanobodies
(REF_Nbs) cloned from the parent library and VEGAS isolates
to the amino acid frequency distribution of 1,346 deposited
Llama glama VhH sequences from >50 animals (Table S4). Five
positions with >99% sequence conservation across populations
were conserved in the REF_Nb sequences, but were mutated in
the VEGAS evolved sequences (Figure 4C). Both sequence anal-
ysis methods demonstrate that the VEGAS-derived nanobodies
were not original to the library but evolved from that initial pool of
nanobody cDNAs.
Positive Allosteric Modulation of GPCRs by
VEGAS-Evolved Nanobodies
Using VEGAS, we produced 8 nanobodies targeted against 3
independent GPCRs in less than 1 week. Here, we interrogate
their physical and molecular interactions with each target and
provide a detailed characterization of the mechanism of VGS-
Nb2, a positive allosteric modulator of the 5-HT2A serotonin
receptor.
First, we established whether the VEGAS-evolved nanobodies
directly associated with their intended GPCR targets via biolumi-
nescence resonance energy transfer (BRET). For BRET, GPCR-
RLuc fusions and increasing concentrations of mVenus nano-
body (mVenus-Nb) fusion proteins were co-transfected in to
HEK293T cells. We observed a strong association between
mVenus-VGS-Nb2 and 5-HT2A-RLuc, but no association to the
closely related serotonin 2B (5-HT2B) receptor (Figure 5A). Addi-
tion of the agonist serotonin (5-HT) at 1 mM or above (Figures 5A
and S5A) had no effect on VGS-Nb2 association to either 5-HT2A
or 5-HT2B. We also observed association between mVenus-
VGS-Nb6 and GPR68-RLuc at pH 8, but no association of the
nanobody to 5-HT2A, the protein used to develop the initial nano-
body library for directed evolution (Figure 5B). GPR68 activity
increases with increasing pH (Huang et al., 2015b), we therefore
stimulated our BRET assay with a pH 6 buffer and observed an
increased association between mVenus-VGS-Nb6 and GPR68-
RLuc (Figure 5B). Low, non-specific interaction of the DRD2-
targeted nanobodies VGS-Nb7 and VGS-Nb8 was also
observed (Figures S5C and S5D). However, VGS-Nb7 and
VGS-Nb8 both increase SRE activity in the presence of DRD2
(Figure S5J) through an unknown mechanism.
The serotonin 2A (HTR2A, 5-HT2A) receptor is a GPCR of sig-
nificant importance to mental health, disease, pharmacology,
and homeostatic biology (McCorvy and Roth, 2015). Structures
of 5-HT2A and closely related 5-HT2-family receptors 5-HT2B
(Wacker et al., 2013) and 5-HT2C (Peng et al., 2018) have yet to
be obtained for their active states. Using VEGAS we have iden-
tified a nanobody that binds active 5-HT2A, but not 5-HT2B. We
therefore further characterized the 5-HT2A nanobody VGS-Nb2.
We first confirmed the interaction between 5-HT2A and VGS-




Figure 4. VEGAS for Evolution of Active-State Nanobodies
VEGAS was used to develop nanobodies that selectively activate diverse GPCR targets from a single cDNA library.
(A) Deep sequencing of the nanobody cDNA library used for VEGAS. 20 million reads were aligned to VEGAS-derived clones and plotted as % mismatch. Data
was analyzed with score cut-offs (CO) of 25, 50, and 100 (STAR Methods). Grey blocks are gaps in alignment as per (C). Black blocks are regions with mapped
reads <2,000 counts (<0.0001%). Symbols^and * mirror those on (C). Bottom histogram, percent total mapped reads for each alignment.
(B) Serum-response element (SRE) reporter assay. Nanobody:receptor:reporter transfection ratio of 5:1:1. FLuc production equates to relative receptor acti-
vation. Data are represented as mean ± SEM, N = 3.
(C) Amino acid sequence alignment of library (REF_NB#) and VEGAS-derived clones. Shading: 100% (red), >75% (yellow), <75% (white). Variations identified in
VEGAS, but not reference sequence, derived clones at positions of high genetic conservation (see Table S4) are annotated,̂ >99%conserved, * >95%conserved.
Nanobody secondary structure annotated above, retrieved from PDB 3P0G, chain B. Complementarity determining regions (CDRs) annotated below. b, beta
sheet. TT, strict b-turn.





Figure 5. Positive Allosteric Modulation of
GPCRs by VEGAS-Evolved Nanobodies
VEGAS-derived nanobodies were tested for direct
association and allosteric modulation of their
targets.
(A) Bioluminescence resonance energy transfer
(BRET) association assay between 5-HT2A-
RLuc or 5-HT2B-RLuc and mVenus-VGS-Nb2 at
increasing transfection ratios of nanobody. Data
are represented as mean ± SEM, N = 3. Symbols
for 5-HT2B-Rluc data underlie those for the +1 mM
5-HT data.
(B) Bioluminescence resonance energy transfer
(BRET) association assay between GPR68-RLuc
or 5-HT2A-RLuc and mVenus-VGS-Nb6. Data are
represented as mean ± SEM, N = 3.
(C) Serum response element (SRE) reporter assay.
RLuc production equates to relative receptor
activation. Data are represented as mean ± SEM,
N = 3.
(D) Saturation radioligand binding assay. 5-HT2A-
Gaq membrane treated with vehicle or 5 mM VGS-
Nb2. 5-HT2A; Kd = 0.30 nM, Bmax = 1,333 fmol/mg.
5-HT2A+VGS-Nb2; Kd = 0.566 nM, Bmax = 1,993
fmol/mg. Data are represented as mean ± SEM,
N = 3, *p < 0.05.
(E) Competitive radioligand binding assay. 5-HT2A
and 5-HT2A-Gaq membrane treated with vehicle or
7.5 mM VGS-Nb2 labeled with 1 nM [3H]ketanserin
and increasing concentrations of DOI. Data are
represented as total-count normalized means ±
SEM, N = 3.
See also Figure S5, Table S5, and Data S1 and S2.blot (Figure S5B) and mass spectrometry (Figure S5E). These as-
says confirmed a stable interaction between the receptor and 
nanobody. These assays were performed in the absence of 
ligand, confirming our previous BRET observation that the 
interaction is ligand-independent. This is consistent with our 
directed evolution selection paradigm, which required a nano-
body capable inducing receptor activity in the absence of ligand.
5-HT2A couples to Gaq and b-arrestin to transduce its signal in 
cells (Wacker et al., 2017b). We tested whether VGS-Nb2 asso-
ciation to 5-HT2A was Ga-dependent using GaqD/11D/sD knockout 
cell lines (Alvarez-Curto et al., 2016) in BRET recruitment assays 
(Figure S5A), coIP by western blot (Figure S5B), and mass spec-
trometry (Figure S5E). In all three studies, no appreciable differ-
ence in VGS-Nb2 association was detected. Notably, as with all 
epistasis experiments, knockout cell lines frequently adapt to 
gene loss by augmenting signaling pathways (Duncan et al., 
2012; Luttrell et al., 2018). However, from the additional proteins
identified in HEK-T and GaqD/11D/sD cells (Table S5), no canonical 
GPCR transducers were identified. We concluded from this anal-ysis that VGS-Nb2 does not stabilize, or
lock, a transducer-coupled state. This
aligns with the evolved purpose of this
nanobody to act as a positive allosteric
modulator (PAM) of 5-HT2A rather than
inhibit transducer cycling.
To further validate VGS-Nb2 as a 5-HT2A PAM, we first assessed its ability to positively modulate
SRE signaling downstream of 5-HT2A. At Nb ratios demon-
strated to bind <50% of 5-HT2A (Figure 5A), VGS-Nb2
increased the agonist-mediated SRE response by up to 2-fold
(Figure 5C). This SRE signal could originate from Gaq and/or
b-arrestin pathways. We assessed the effect of the nanobody
using calcium and arrestin recruitment assays, respectively.
VGS-Nb2 allosterically enhanced 5-HT2A calcium release (Fig-
ure S5F), a Gaq-mediated signal response. Conversely, VGS-
Nb2 diminished mVenus-b-arrestin2 recruitment to the 5-
HT2A-RLuc fusion protein as a function of time (Figure S5G)
and agonist concentration (Figures S5H and S5I). From these
experiments, we hypothesized that VGS-Nb2 stabilizes the
high-affinity Gaq-coupled state of the receptor.
Unliganded receptors are rarely found in their active, or high-
affinity, conformational state (Manglik et al., 2015). However, ra-
diolabeled ligands can be used to probe and quantify high-
affinity receptor sites. The number of these sites increases
when allosteric effectors, such as Gaq or nanobodies, are bound
to the receptor (Che et al., 2018; Staus et al., 2016; Strachan
et al., 2014). To test whether VGS-Nb2 stabilizes the 5-HT2AGaq-
coupled active state, as predicted from our functional data, we
first employed radioligand saturation binding using the partial
agonist [3H]LSD (Figure 5D). Membranes from cells transfected
with 5-HT2A fused to its transducer Gaq (5-HT2A-Gq) were incu-
bated with increasing concentrations of [3H]LSD ± 5 mM purified
VGS-Nb2. As shown in Figure 5D, VGS-Nb2 increased labeled
agonist binding sites by 50%. This increase in high-affinity
agonist binding sites was additionally confirmed through
competitive radioligand binding wherein 5-HT2A and 5-HT2A-
Gaq membranes were incubated with ± 7.5 mM purified VGS-
Nb2 (Figure 5E). In competition with the radiolabeled 5-HT2A
antagonist [3H]ketanserin, the selective agonist DOI bound the
5-HT2A receptor with a half maximal inhibitory concentration
(IC50) equal to 550 nM. Neither a local excess of Gaq (DOI
IC50 = 307 nM, p = 0.1264) nor the addition of purified VGS-
Nb2 (DOI IC50 = 746 nM, p = 0.3957) significantly affected DOI
binding. However, in the presence of both Gaq and VGS-Nb2,
50% of the available ligand binding sites were stabilized in
the high-affinity conformation that bound DOI with an
IC50 = 0.15 nM.
We have therefore demonstrated the directed evolution of
multiple functionally distinct nanobody sequences against
GPCRs using VEGAS. Of these, we have characterized VGS-
Nb2 as aGaq-dependent positive allosteric modulator of 5-HT2A.
DISCUSSION
Here, we demonstrate the development of a system for facile
directed evolution in mammalian cells: VEGAS. Leveraging the
alpha virus Sindbis as a vector for heredity, mutagenesis, and se-
lection, we succeeded in evolving context-dependent functions
for three independent classes of proteins. Our evolution targets
were primary (tTA), secondary (GPCR), and tertiary (Nbs) interac-
tors to downstream outputs, demonstrating the ability of VEGAS
to provide tools at multiple levels of cell signaling. Our primary
system evolved tTA to engage with TETO7 in the presence
of >1 mM DOX. Our secondary system evolved the GPCR
MRGPRX2 to constitutively activate the serum response element
via endogenous signaling pathways. Our tertiary system evolved
nanobodies to selectively activate GPCRs, which in turn acti-
vated the serum response element via endogenous signaling
pathways. Together, these applications showcase the ease
and power of the VEGAS system as a tool for enabling directed
evolution campaigns across a broad range of potential mamma-
lian applications.
Directed evolution allows genetic sequences to evolve under
selective pressure in an appropriate context. Through this pro-
cess we are able to guide solutions to otherwise intractable
biological problems (Hammer et al., 2017; Kan et al., 2016; Mat-
sumoto et al., 2015; Shapiro et al., 2010). However, powerful sys-
tems for directed evolution in a mammalian cell context have
lagged behind unicellular systems. VEGAS offers three major
advantages for the directed evolution of biomedical tools and
therapies.
First, VEGAS evolves within the signaling framework of
the host cell. Signaling proteins never operate in isolation, butas interacting heteromeric complexes, to transfer information
through the cell (Garrington and Johnson, 1999; Pawson and
Scott, 1997; Purvis and Lahav, 2013; Varnait _e and MacNeill,
2016). The timing, location, and kinetics of these interactions is
critical to performance and cannot be easily replicated in non-
native environments. In addition, we can take advantage of the
negative feedback (Amit et al., 2007; Behar et al., 2007; English
et al., 2015; Ferrell, 2002; Howell et al., 2012; Subramaniam
et al., 1989) mechanisms built in to endogenous signaling
pathways to encode viral selection—as was done for both
MRGPRX2- and nanobody-directed evolution in this study.
Second, VEGAS is wholly dependent on the host cell for trans-
gene maturation (Garcia-Moreno et al., 2013). Directed evolution
performance can falter when transferring tools evolved in one
context to another (Armbruster et al., 2007). This may be a
consequence of improper trafficking, failed compartmentaliza-
tion, incorrect protein maturation, or absence of non-native
co-factors.With VEGAS,mammalian translation is a requirement
of the evolved product.
Third, VEGAS selection is constant and highly mutagenic,
enabling it to overcome many of the pitfalls inherent to complex
fitness landscapes (Romero and Arnold, 2009; Tracewell and
Arnold, 2009). To avoid dead-ends and early fitness bias,
directed evolution systems must sample toward saturation
whenever possible. This directed evolution paradigm helps to
maintain diversity by preserving even poor performing early evo-
lution variants, which may ultimately rise to the highest fitness
peaks. This is achieved with VEGAS, in part, because each
host cell operates as a closed system. This allows evolved solu-
tions derived in each cell to compete in the subsequent rounds—
even when vastly superior solutions may have arisen elsewhere
within the same selection cycle.
There are many potential applications of the VEGAS system.
Sindbis virus has a transgene packaging capacity of >6 kb
(Huang and Summers, 1991), placing few limits on the potential
targets for directed evolution. High value targets would include:
Cas9 variants evolved to better engage endogenous se-
quences (Doudna and Charpentier, 2014; Kleinstiver et al.,
2015; Lee et al., 2018), fluorescent protein variants evolved
for maturity time, photostability, brightness, or wavelength
specificity in human tissue (Drobizhev et al., 2011; Piatkevich
et al., 2017; Shaner et al., 2004, 2008), or designer receptors
exclusively activated by designer drugs (DREADDs) for the che-
mogenetic control of cell signaling (Armbruster et al., 2007;
Roth, 2016).
There also remains significant room for improvement. VEGAS
has performed well with positive genetic selection and, as a syn-
thetic biology system, can be engineered to perform AND and
OR logic gated selection paradigms. It cannot at this time
generate exclusive or NOT logic gated selection paradigms.
Developing a dominant negative selective pressure for VEGAS
will make these modes possible. In addition, a method to tune
the speed of replication would be advantageous for developing
slower phase gene circuits including those coupled to the
cell cycle, metabolism, or other slow-maturing signal classes.
Adapting VEGAS for mammalian cell bioreactors would also
allow it to be applied as a continuous system (Badran and Liu,
2015). Here, we add VEGAS to the growing toolbox of synthetic
biology, filling an essential need for facile directed evolution in a
mammalian context.
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Lipid A Sigma-Aldrich L5399
lysergic acid diethylamide synthetic Wacker et al., 2017b
Methiothepin mesylate salt Sigma-Aldrich M149
n-dodecyl-b-D-maltopyranoside (DDM) Anatrace D319
n-Octyl-b-D-Glucopyranoside Anatrace O311
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TransIT-2020 Transfection Reagent VWR MIR5400
Deposited Data
Raw and analyzed data This paper GEO: GSE123269
Experimental Models: Cell Lines
Hamster: BHK21 ATCC CCL-10
Human: HEK293T ATCC CRL-3216
Human: HEK-Ga11D/sD/olfD/12D/13D gift Asuka Inoue, Tohoku University
Human: HEK-P gift Asuka Inoue, Tohoku University
Human: HTLA gift Richard Axel, Columbia University
Insect: Sf9 cells, suspension in ESF 921 1M cells/mL Expression Systems 94-001S
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See Table S6 N/A N/A
Recombinant DNA
See Table S6 N/A N/A
Other
0.45uM media filters EMD Millipore SCGP00525
10 mg/mL Carbenicillin supplemented LB agar plates Teknova L1010
24-well plates Sigma-Aldrich CLS3527
384-well white plates Black Dog 781098
5% normal goat serum Vector Laboratories S-1000
96-well white plates Black Dog 655098
BamHI-HF NEB R3136
Canted neck culture flasks Sigma-Aldrich CLS430641U
ClaI NEB R0197
CutSmart Buffer NEB B7204
Dulbecco’s Modified Eagle Media (DMEM) VWR 45000
Fetal Bovine Serum (FBS) VWR 89510-186
Filtermat A, GF/C PerkinElmer 1450-421
Immobilon PVDF membranes Sigma-Aldrich IPSN07852
LB Broth ThermoFisher 10855001
MeltiLex Solid Scintillant, for Microbeta PerkinElmer 1450-441
MEM-a with nucleosides ThermoFisher 32571036
myo-inositol-free DMEM Caisson Labs DML13
NheI-HF NEB R3131
NotI-HF NEB R3189
PET-A, FLEX, 96-well clear sample plates PerkinElmer 1450-401C
RNAsin Promega N2111
Sf-900 II SFM media ThermoFisher 10902096
T7 DNA Ligase NEB M0318
XbaI NEB R0145LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Justin 
English (jgenglis@email.unc.edu).
METHOD DETAILS
Molecular Biology & Plasmid Construction
All standard plasmids were constructed via PCR amplification of the desired amplicons using PrimeSTAR Max DNA polymerase 
(Takara Bio, #R045) and primers (Table S6, Eton Biosciences). Ligation of backbones and amplicons was performed using NEBuilder 
HiFi DNA Assembly Master Mix (NEB, #E2621). Clones were isolated by transformation of ligated DNA to One Shot Stbl3 Chemically 
Competent E. Coli (Thermofisher, #C737303) and selected on LB agar plates supplemented with 100mg/mL carbenicillin (Teknova 
L1010). Individual colonies were grown shaking at 37C overnight in liquid LB broth (ThermoFisher, 10855001) supplemented with 
100 mg/mL carbenicillin (GoldBio, C-103-25). Plasmids were purified with QIAprep Spin Miniprep Kits (QIAGEN, #27104) or 
PowerPrep HP Plasmid Maxiprep Systems (OriGene, #NP100010), dependent on downstream application. For construction of 
viral-sequence containing vectors see specific methods sections. All constructs were designed and confirmed via Sanger 
sequencing alignment (Eton Biosciences) using Benchling (https://Benchling.com). The list of plasmids used in this study can be 
found on Table S6, those necessary to perform VEGAS directed evolution have been made available at Addgene.org.
General Cell Culture
All cells were grown in a humidified 37C incubator with 5% CO2 using media supplemented with 100 I.U./mL penicillin and
100 mg/mL streptomycin (ThermoFisher, #15140122), unless otherwise indicated. The human cell lines HEK293T (ATCC, #CRL-
3216), HTLA (kindly provided by Dr. Richard Axel, Columbia Univ.), HEK-Gaq/11/sD, and HEK parental (HEKp, both kindly provided
by Asuka Inoue, Tohoku Univ.) were maintained in DMEM (VWR, #45000) containing 10% fetal bovine serum (FBS, VWR,
#89510-186). HTLA cells were additionally supplemented with 5 mg/mL Puromycin (Gemini, 400-128P) and 100 mg/mL Hygromycin
B (KSE, 98-923). The hamster cell line BHK21 (ATCC, #CCL-10) was maintained in MEM-a with nucleosides (ThermoFisher,




pTSin (pTransgenicSindbis, Table S6), a transgene-free variant of pSinRep5 (kindly provided by Mark Heise, UNC Chapel Hill) (see
Bredenbeek et al., 1993), was used as the base plasmid for the construction of all transgenic Sindbis virus packaging experiments.
Each transgene of interest was subcloned to pTSin via PCR amplification adding 50-NotI & 30-ClaI cut sites or double NotI sites. The
amplicon and pTSin were both digested overnight at 37C with NotI-HF (NEB, #R3189) and ClaI (NEB, #R0197). The digested DNA
fragments were purified using the QIAquick Gel Extraction Kit (QIAGEN, #28115) and ligated with T7 DNA ligase (NEB, #M0318).
Clones were selected and confirmed as described previously.
Preparation of mRNA
Our preparation of RNA for Sindbis virus packaging is modified from previous methods (Bredenbeek et al., 1993). pTSin plasmids
containing transgene, as well as pSinHelper and pSinCapsid (both kindly provided by Mark Heise, UNC Chapel Hill), must be line-
arized before converting them to mRNA for viral packaging. Linearization was accomplished by mixing 3mg of plasmid with 2 mL
XbaI (NEB, #R0145), 8 mL CutSmart Buffer (NEB, #B7204), raised to 80 mL with nuclease-free water (hereafter H2O, NEB, #B1500)
and incubated at 37C for 24 hr. The linearized DNA was extracted by adding 20 mL H2O to the digestion mix, followed by 100 mL
UltraPure Phenol:Chloroform:Isoamyl Alcohol (25:24:1 w/v, ThermoFisher, #15593031). The mixture was vortexed for 15 s, centri-
fuged at 13,000 x g for 5 min, and the top aqueous phase was transferred to a new tube. The extraction was then repeated. The
extracted DNA was then treated with 10mL 3M sodium acetate (pH 5.2), mixed by inversion, and precipitated with 220mL 100%
ethanol. The precipitant was kept at 80C for a minimum of 20 min (or held indefinitely for future use). The DNA:ethanol mixture
was then centrifuged at 13,000 x g for 10 min at 4C. The liquid was gently aspirated from the pellet and the retained pellet was
washed with 300mL 75% ice-cold ethanol prior to centrifugation at 13,000 x g for 3 min at 4C. The wash was aspirated and the pellet
was resuspended in 10mL RNAsin (Promega, #N2111) treated H2O (1:10, v:v). DNA was then immediately in vitro transcribed
to mRNA.
Conversion of linearized pTSin transgene plasmids to mRNA was performed using the Ambion mMessage mMachine in vitro
mRNA transcription kit (Fisher, #AM1340). Reagents were added in the following order at room temperature: 1mL reaction buffer,
5mL CAP/dNTP mix, 1mL GTP, 10mL linearized pTSin vector, and 0.7mL enzyme. The reaction was incubated at 37C for 1 hr and
then used immediately or stored at 80C until needed.
Packaging to Sindbis Viral Particles
To package pTSin in to viral particles pTSin, pSinHelper, and pSinCapsid mRNA must be electroporated in to BHK21 cells. One day
prior to electroporation BHK21 cells were split to canted-neck culture flasks seeded at 5x105 cells/dish. One flask is prepared per
desired electroporation. On the day of electroporation cells were washed with 10mL Ca2+/Mg2+ free DPBS (ThermoFisher,
#14190144), disassociated with trypsin (VWR, #45000-660), rinsed with 7mL ice-cold DPBS, and held on ice. Cells were centrifuged
at 500 x g for 5 min at 4C. Cell pellet was resuspended in 10mL ice-cold DPBS and centrifuged at 500 x g for 5 min 4C. The DPBS
wash was repeated 2 additional times. Before the final wash, cells were counted by hemocytometer. The washed cell pellet was then
resuspended in ice cold Neon E1 electroporation buffer (ThermoFisher, #MPK10096) to 5x106 cells/mL and aliquoted 115mL for each
transgene to be packaged. To each cell aliquot 10mL of pTSin, pSinHelper, and pSinCapsid mRNA were added, pipette mixed, and
electroporated with a Neon Transfection System (ThermoFisher, #MPK5000) set to 1400V, 10 width, 3 pulses. Electroporated cells
were incubated at room temperature for 10 minutes and then applied to 25mL pre-incubated serum-free MEM-a media (Thermo-
Fisher, #32571036) supplemented with 10% tryptose phosphate broth and pen/strep in canted neck culture flasks (Sigma-Aldrich,
#CLS430641U). After 24 hr media was decanted, 0.45mm filtered (EMDMillipore, #SCGP00525), and stored at 4C for no longer than
1 month for use in downstream applications.
Sustained Passage of Sindbis for Directed Evolution and Transgene Isolation
Construct Design
For sustained passage and selection by directed evolution the Sindbis virus structural genome (pG100, SSG; 7662-11718 of full
length Sindbis virus genome GenBank: MF459683.1, kindly provided by Mark Heise, UNC Chapel Hill) was subcloned using PCR/
HiFi assembly as described above to mammalian expression plasmids possessing either CMV (pCDNA3.1), TETO7 (pTRE3G-BI-
ZsGreen1), or SRE (pGL4.33) promoters (see Table S6 for source and mapping information).
Cell Culture and Selection
One day prior to selection 5x105 BHK21 cells were plated in canted neck culture flasks (Sigma-Aldrich, #CLS430641U). The following 
day 10mg of the appropriate SSG plasmid was transfected in to the cells using the TransIT-2020 Transfection Reagent (VWR, 
MIR5400). The transfected cells were incubated for six hr before removing all media, rinsing the cells with PBS, and then applying 
the appropriate titer of virus diluted to 2mL in serum-free MEM-a media supplemented with 10% TPB, pen/strep, and either doxy-
cycline HCl (Sigma-Aldrich, #D3447), (+)-morphine (NIDA Drug Supply, 9300-012), or vehicle. For GPR68-targeted selection, media 
was additionally supplemented with 2mg/L sodium bicarbonate and equilibrated to pH 8.0 in 5% CO2 overnight prior to use. After 
incubating 1 hr with intermittent rocking 23mL of additional supplemented media was added and the cells were incubated for 
24 hr. Following culturing and viral propagation the cell culture media is decanted, 0.45mm filtered, and stored at 4C for no longer 
than 1 month.
Transgene Isolation
Using the MagMax Viral RNA Isolation Kit (ThermoFisher, AM1939) a 1mL aliquot of the viral stock was processed to collect a viral 
RNA sample. The purified RNA was maintained, precipitated in 100% EtOH at 80C, until use in downstream applications unless 
noted otherwise. Isolating only translated transgenes from the viral pool is critical for the success of VEGAS. To isolate positively 
selected transgene sequences we used a forward primer annealing to the 26S promoter (26S-F, 50-atctctacggtggtcctaaatagt-30) 
alongside 8 reverse primers (pooled as ‘‘SinRev’’) annealing to the conserved RNA structural components of the viral 30 UTR (See 
Table S6). Production of a cDNA library from the Sindbis virus RNA genome with SinRev and subsequent PCR amplification with 
26S-F & SinRev were performed in series using the SuperScript IV One-Step RT-PCR System (Invitrogen, #12594025). Amplicons 
and pCDNA3.1 were digested with NheI-HF (NEB, #R3131) and BamHI-HF (NEB, #R3136), gel purified, and ligated together. 
Colonies were selected, cultured, plasmids were purified, and identified by sequencing as described above. Any clone appearing 
R 2 times out of 12 clones was selected for functional screening.
RNA Deep Sequencing
Sample Processing
Samples were prepared as follows. For EGFP mutation analysis, the pTSin-EGFP construct was independently packaged via NEON 
electroporation into three separate cell populations as described above, using fresh mRNA prepared on the day. During packaging, 
viral samples were decanted and 0.45 mM filtered at 3, 6, 12, 24, and 36 hr from each of the three independently grown cell flasks. At 
each collection time point the cells were washed with PBS and returned to incubate with fresh media. Viral RNA for all time points and 
replicates was collected simultaneously using the MagMax Viral RNA Isolation Kit (ThermoFisher, AM1939) from a 1mL aliquot of 
each viral stock. For nanobody library analysis, the pTSin-Nb library mRNA used for subsequent directed evolution experiments 
was purified and used for sequencing.
The purified RNA samples, synthesized mRNA, and pTSin-EGFP vector template were immediately amplified as described above 
with the SuperScript IV One-Step RT-PCR System (Invitrogen, #12594025) using 26S-F and the SinRev primer pool.
For mutation rate analysis the EGFP transgene amplicons were processed using a KAPA HyperPlus kit (KAPABiosystems, KK8512) 
with a 30’ digestion period followed by standard size selection with KAPA Pure Beads (KAPABiosystems, KK8001). The resulting 
fragments were barcoded with the Illumina compatible SeqCAP Adapater Kit A & B (KAPABiosystems, 7141530001 and 
07141548001). Samples were normalized, pooled, and processed using a NextSeq NSQ 500/550 Hi Output KT v2.5 300 cycle kit 
(Illumina, 200249808) calibrated to acquire dual-indexed, 2 3 150 bp reads, yielding an average of 4.3 3 108 reads per sample.
For nanobody library analysis the amplicons were > 100bp size-selected using Agencourt AMPure magnetic beads (Beckman 
Coulter, #A63881). The purified DNA was diluted to 10ng/mL in 10mM Tris, 1mM EDTA, pH 7.5 sonication buffer and sheared to 
150bp fragments on a Bioruptor Pico sonication device (Diagenode, #B01060010) using a 30’’/30’’ cycle program for 30 cycles at 
4C. The sheared DNA was then used for library construction using a KAPA Hyperprep Kit (Roche, #KK8500) and Illumina TruSeq 
indexed adapters (IDT, HPLC purified) following the manufacturer’s recommended protocol. Samples were normalized and pro-
cessed using 12-plex, single-indexed, 1 3 150 bp Illumina NextSeq500 sequencing.
The EGFP experiment sequence data was initially processed for exact matching paired-end reads > 25bp in length. The longest 
perfect match from each read pair was isolated and the remaining non-matching sequences were omitted from further analysis. The 
truncated reads were aligned to sense and anti-sense EGFP and Sindbis genome reference sequences using a Smith-Waterman 
algorithm (Smith and Waterman, 1981) on the UNC Longleaf Linux Cluster (UNC ITS). Alignment score weighting was m3, x1, o5, 
e1 for correct match (m), mismatch penalty (x), insert/deletion penalty (o), and gap extension penalty (e). Reads were associated 
with their high scoring reference sequence. The sequences aligning to anti-sense EGFP were reverse-complemented. All EGFP align-
ing reads were then re-aligned to the EGFP reference sequence and a sequence where EGFP was excised (TGDEL). Sequences 
scoring best for the sense EGFP reference were then used to retrieve individual base position, deletion, and insertion counts for 
the EGFP transgene. No score cut-offs were implemented.
The nanobody experiment sequence data was aligned to the cloned nanobody reference sequence using a Smith-Waterman al-
gorithm (Smith and Waterman, 1981) on the UNC Longleaf Linux Cluster (UNC ITS). Alignment score weighting for all nanobodies was 
m1, x5, o5, e5 for correct match (m), mismatch penalty (x), insert/deletion penalty (o), and gap extension penalty (e). Sequence reads 
containing the 30 barcode and vector backbone were trimmed and the final alignments were designated with varying score cut-offs as 
described in Figure 4A.
Data were analyzed on Graphpad Prism 8. The mutation frequency data per time point (Figure 1C) statistics were calculated using
One-Way ANOVA with Geisser-Greenhouse correction and Sidak multiple comparisons correction. Multiplicity adjusted P values for
each comparison are p < 0.0001 for all significant comparisons, using family-wise significance and confidence level set to 99.9%. The
mutation type per base reads data (Figure 1D) was plotted as individual replicates. The values represent the number of total substi-
tutions divided by the number of total reads for the mutated base per replicate and time point. Statistics were calculated within each
base substitution group using Two-Way ANOVA and Tukey’s multiple comparisons correction with one family per column (substitu-
tion type). Aminimummultiplicity adjusted P value (a = 0.05) was applied for each comparison. Themutations base-1/time (Figure 1E)
data was plotted with a linear regression model for mean ± SD of N = 715 measures with 99% confidence band displayed. Data in
Figures S1B–S1D are residuals of the data displayed in Figure 1 and no statistical analysis was performed. For Figures S1E–S1G the
number of mutations observed per total reads at the indicated read length are plotted with a linear regression model beginning at the
observed linear range of read length 50. 95% confidence bands are displayed for each time point.
Quantification of Viral RNA via qRT-PCR
Quantification of Sindbis viral genomic RNA by TaqMan qRT-PCR was performed as described previously (Sane et al., 2012)
with modification. We designed a probe and primer pair specific for the packaging signal sequence spanning g.138-a.269 of
nsP1 in pTSin; Probe: 50-/5HEX/ATTTTGGAC/ZEN/ATAGGCAGCGCACC/3IABkFQ/-30, Forward: 50-GTTCCTACCACAGCGACG-30,
Reverse: 50-GGTACTGGTGCTCGGAAAAC-30 (IDT) (see Table S6). Sindbis virus containing media was diluted across 3 3 10-fold
serial dilutions, 4 replicates each, mixed directly with TaqMan Fast Virus 1-Step Master Mix (ThermoFisher, #4444432) and cycled
on a BioRad CFX96 Touch RT-PCRmachine (BioRad). Serially diluted (1012-106M) in vitro transcribed Sindbis virus RNA reference
samples were present on each sample plate. Standard curves were calculated on CFX Manager (BioRad) and used to calculate and
report genomes/mL for each sample.
tTA Reporter Assay
Thewild-type and R7_G8 tetracycline transactivator (tTA) sequences were subcloned in pCDNA3.1. The reporter was constructed by
subcloning luc2p from SRE-luc2p (Promega, pGL4.33) over the ZsGreen1 CDS of pTRE3G-BI-ZsGreen1 (Takara, 631339) to create
pTRE3G-BI-luc2p. The day before transfection, HEK293T cells were split to yield approximately 9x106 cells/15-cm plate next day.
The following day cells were transfected with 10mg DNA per 15-cm, 5mg of pTRE3G-BI-luc2p and either 5mg of WT or R7 constructs
using TransIT-2020. Six hours after transfection media and transfection reagents were removed, cells were washed with PBS, disso-
ciated using versene (ThermoFisher, 15040066), centrifuged and resuspended in DMEM supplemented with 1% dialyzed FBS.
Transfected cells were then plated onto poly-L-lysine-coated 384-well white clear bottom cell culture plates at a density of
10,000 cells/well in a total of 20ml. Doxycycline HCl solutions were prepared in plating media at 2 x and added to cells (20 mL per
well) for overnight incubation. After 20-22 hr overnight incubation, media and drug solutions were removed from plates and 20ml
per well of 1:20 diluted Bright-Glo reagent (Promega, E2620) was added per well. The plate was incubated for 20 min at room
temperature in the dark before being counted using a luminescence counter. Results (relative luminescence units) were plotted
as a function of drug concentration and analyzed using ‘‘log(inhibitor) versus response’’ in GraphPad Prism 8.0.
Transcription Factor Reporter Primary Screen
The MRGPRX2, DRD2, 5-HT2A, and GPR68 constructs originated from their respective PRESTO-TANGO plasmids (Kroeze et al.,
2015), from which the C-terminal V2Tail-TEV-tTA sequence was removed by PCR mutagenesis. The transcription factor reporter
constructs were purchased from Promega (see Table S6). Two days before transfection, HEK293T cells were split to yield approx-
imately 9x106 cells/15-cm plate in 2 days. On the day of transfection each well of a poly-L-lysine-coated 384-well white clear bottom
cell culture plate received 30ng of DNA,15ng of one transcription factor reporter and 15ng of either GPCR or pCDNA3.1, pre-incu-
bated with TransIT-2020. One plate was prepared for each time point, with 8 wells of GPCR and 8 wells of empty vector for each
reporter construct. The prepared cells were then washed with PBS, dissociated using trypsin, centrifuged, and resuspended in
DMEM supplemented with 1% dialyzed FBS. Cells were seeded in the DNA pre-loaded plates at 10,000 cells/well to a final volume
of 40 mL and incubated for 24 hr. The following day single drug concentrations and vehicle (DMSO) were prepared in drug buffer
(1 x HBSS, 20 mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4) at 3 x and added to cells (20ml per well) at the appropriate
time point for each plate. For each reporter 4 replicates of drug treated and 4 replicates of vehicle were added for each transfection
condition at each time point. After incubation, media and drug solutions were removed from plates and 20ml per well of BrightGlo
reagent (purchased from Promega, after 1:20 dilution) was added per well. The plate was incubated for 20 min at room temperature
in the dark before being counted using a luminescence counter. Results (relative luminescence units) were plotted as a function of
time in GraphPad Prism 8.0.
SRE Reporter Assay
The GPCR constructs from the transcription factor reporter primary screen were used in these assays. Nanobody constructs were
direct clones from Sindbis virus transgene isolation to pCDNA3.1. The day before transfection, HEK293T cells were split to yield
approximately 9x106 cells/15-cm plate next day. The following day cells were transfected with 15 mg DNA per 15-cm dishes; 5 mg
of SRE-luc2P (Promega, pGL4.33), 5 mg of GPCR, and an appropriate ratio of Nb and empty vector to 5ug. The next day, media
and transfection reagents were removed, cells were washed with PBS, dissociated using versene, centrifuged and resuspended in 
DMEM supplemented with 0.1% dialyzed FBS. Transfected cells were then plated onto poly-L-lysine-coated 384-well white clear 
bottom cell culture plates at a density of 10,000 cells/well in a total of 40ml. The cells were incubated for 12 hr and then developed 
for untreated assays or received drug stimulation. Drug solutions were prepared in drug buffer (1 x HBSS, 20 mM HEPES, 0.1% BSA, 
0.01% ascorbic acid, pH 7.4) at 3 x and added to cells (20ml per well) for overnight incubation. After 6 hr incubation, media and drug 
solutions were removed from plates and 20 mL per well of BrightGlo reagent (purchased from Promega, after 1:20 dilution) was 
added per well. The plate was incubated for 20 min at room temperature in the dark before being counted using a luminescence 
counter. Results (relative luminescence units) were plotted as a bar graphs or as a function of drug concentration and analyzed using 
‘‘log(agonist) versus response (three parameters)’’ in GraphPad Prism 8.0.
TANGO b-arrestin recruitment assay
The MRGPRX2 Tango construct, which contains the TEV cleavage site and the tetracycline transactivator (tTA) fused to the 
C terminus of the receptor, were designed and assays were performed as previously described (Kroeze et al., 2015; Lansu et al., 
2017). Each VEGAS-derived MRGPRX2 mutant was subcloned over the wild-type sequence via HiFi assembly. HTLA cells express-
ing TEV fused- b-Arrestin2 and a tetracycline transactivator-driven luciferase (kindly provided by Dr. Richard Axel, Columbia Univ.) 
were grown in HTLA media (10% FBS DMEM containing 5 mg/mL Puromycin and 100 mg/mL Hygromycin B). The day before trans-
fection, HTLA cells were split to yield approximately 9x106 cells/15-cm plate next day. The following day cells were transfected with 
10mg DNA per 15-cm with MRGPRX2 Tango, or one of the VEGAS derived mutants, using TransIT-2020. The next day, media and 
transfection reagents were removed, cells were washed with PBS, dissociated using versene, centrifuged and resuspended in 
DMEM supplemented with 1% dialyzed FBS. Transfected cells were then plated onto poly-L-lysine-coated 384-well white clear bot-
tom cell culture plates at a density of 10,000 cells/well in a total of 40ml. The cells were incubated for 12 hr before receiving drug stim-
ulation to allow for recovery and adherence to the plate. Drug solutions were prepared in drug buffer (1 x HBSS, 20 mM HEPES, 0.1%
BSA, 0.01% ascorbic acid, pH 7.4) at 3 x and added to cells (20ml per well) for overnight incubation. Drug solutions used for the Tango 
assay were exactly the same as used for the SRE assay, which was conducted in parallel to the Tango assay. After 6 hr incubation, 
media and drug solutions were removed from plates and 20 mL per well of BrightGlo reagent (purchased from Promega, after 1:20 
dilution) was added per well. The plate was incubated for 20 min at room temperature in the dark before being counted using a lumi-
nescence counter. Results (relative luminescence units) were plotted as a function of drug concentration, normalized to % wild-type 
stimulation, and analyzed using ‘‘log(agonist) versus response (three parameters)’’ in GraphPad Prism 8.0.
Calcium flux assay
Assays were designed and performed as previously described (Wacker et al., 2017b), using the same 5-HT2AR stable cell line 
created with the Flp-In 293 T-Rex Tetracycline inducible system (Invitrogen). The day before transfection, 5-HT2AR cells were split 
to yield approximately 9x106 cells/15-cm plate next day. The following day cells were transfected with 8 mg DNA per 15-cm with 
adjusted ratios of empty vector (pCDNA3.1) or pCDNA3.1-VGS-Nb2 using TransIT-2020. Six hours after transfection, 1 mM final con-
centration of doxycycline HCl was applied to induce receptor expression. The next day, media and transfection reagents were 
removed, cells were washed with PBS, dissociated using versene, centrifuged and resuspended in DMEM supplemented with 
0.1% dialyzed FBS. cells were seeded in 384-well poly-L-lysine plates at a density of 10,000 cells/well at least 16-24 hr before 
the calcium flux assay. On the day of the assay, the cells were washed in FLIPR buffer (1 x HBSS, 2.5 mM probenecid, and 
20 mM HEPES, pH 7.4), pre-treated with the 1 mM alkylating agent phenoxybenzamine (Sigma-Aldrich, B019) for 30 min, washed 
again in FLIPR buffer and then incubated with 20mL/well Fluo-4 Direct dye (ThermoFisher, F10471) reconstituted in FLIPR buffer 
for 1 hr at 37C. After dye loading, cells were placed in a FLIPRTETRA fluorescence imaging plate reader (Molecular Dynamics). 
Drug dilutions were prepared at 3 x final concentration in drug buffer (1 x HBSS, 20 mM HEPES, 0.1% BSA, 0.01% ascorbic 
acid, pH 7.4), aliquoted into 384-well plates. and placed in the FLIPRTETRA for drug stimulation. The fluidics module and plate reader 
of the FLIPRTETRA were programmed to read baseline fluorescence for 10 s (1 read/s), then 10ml of drug/well was added and read for 
5 min (1 read/s). Fluorescence in each well was normalized to the average of the first 10 reads (i.e., baseline fluorescence). Then, the 
maximum-fold increase, which occurred within the first 60 s after drug addition, was determined and fold over baseline was plotted 
as a function of drug concentration. Data were analyzed using ‘‘log(agonist) versus response (three parameters)’’ in Graphpad 
Prism 8.0.
Bioluminescence resonance energy transfer association assay
Assays were designed and performed as previously described (Che et al., 2018), with additions. The day before transfection, 
HEK293T cells were split to yield approximately 9x106 cells/15-cm plate next day. The following day cells were transfected with 
12 mg DNA per 15-cm dishes; 2 mg of GPCR-RLuc DNA held constant and an adjusted ratio of empty vector (pCDNA3.1) or 
pCDNA3.1-mVenus-Nb using TransIT-2020. The next day, media and transfection reagents were removed, cells were washed 
with PBS, dissociated using versene, centrifuged and resuspended in DMEM supplemented with 1% dialyzed FBS. Transfected cells 
were plated in poly-lysine coated 96-well white clear bottom cell culture plates in plating media (DMEM + 1% dialyzed FBS) at a den-
sity of 40-50,000 cells in 200ml per well and incubated overnight. The next day, media was aspirated and cells were washed twice with 
60mL of drug buffer (1 x HBSS, 20 mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4), then 60mL of drug buffer was added per well,
followed by 30mL of drug (3X) per well, and finally 10mL of the RLuc substrate, coelenterazine h (Promega, S2011, 5 mM final
concentration). Plates were incubated for 5 min to allow for substrate diffusion, and then read for both luminescence at 485 nm
and fluorescent eYFP emission at 530 nm for 1 s per well using aMithras LB940multimodemicroplate reader. The ratio of eYFP/RLuc
was calculated per well and the net bioluminescence resonance energy transfer (BRET) ratio was calculated by subtracting the
eYFP/RLuc per well from the eYFP/RLuc ratio in wells without mVenus-Nb present. The net BRET ratio was plotted as a function
of nanobody concentration using Graphpad Prism 8 (Graphpad Software Inc., San Diego, CA).
Phosphoinositide hydrolysis assay
Phosphoinositide (PI) hydrolysis assays measuring inositol phosphates (IP) were performed using the scintillation proximity assay
(Bourdon et al., 2006; Huang et al., 2009). TheMRGPRX2WT construct was developed from the TANGO system as described above
and mutant constructs were directly subcloned as viral transgenes to pCDNA3.1. The day before transfection, HEK293T cells were
split to yield approximately 9x106 cells/15-cm plate next day. The following day cells were transfected with 5 mg DNA per 15-cm dish
with TransIT-2020. On the day before the assay, transfected cells were seeded into 96-well poly-lysine coated plates at a density of
40-50,000 cells/well in 100mL inositol-free DMEM (Caisson Labs, DML13) containing 1%dialyzed FBS. After 6 hr, an additional 100mL
of label media was added containing 1mCi/well (final concentration) of [3H]-myo-inositol (PerkinElmer, NET1177001MC) in inositol-
free DMEM containing 1% dialyzed FBS and plates were incubated overnight for 16-18 hr. The next day, label media was removed
and cells were washed twice with 60mL of drug buffer (1 x HBSS, 20mMHEPES, 0.1%BSA, 0.01% ascorbic acid, pH 7.4), then 60mL
of drug buffer was added per well. Afterward, 30mL of drug (3X) was added per well and incubated at 37C for 1 hr. To capture IP
accumulation, lithium chloride (10mL/well, 15 mM final concentration) was added 30 min before lysis. The assay was terminated
by replacement of the incubation medium with 40mL of 50 mM formic acid. After overnight incubation at 4C, 10mL of lysates
were added to 96-well flexible, clear microplates (PerkinElmer, 1450-401C) containing 75mL of 0.2 mg/well RNA binding yttrium sil-
icate beads (PerkinElmer), and incubated for 1 hr on a shaker. Afterward, plates were centrifuged at 300 x g for 1 min, and radioac-
tivity was measured using a Wallac MicroBeta Trilux plate reader (PerkinElmer). Data were plotted as counts per minute (CPM) as a
function of drug concentration, and analyzed using ‘‘log(agonist) versus response (three parameters)’’ in GraphPad Prism 8.0.
Surface expression enzyme-linked immunosorbent assay
To confirm cell surface expression of MRGPRX2 and its mutants, immunohistochemistry was done using cells plated on 384-well
plates, as described earlier, at 10,000 cells/well. Cells were fixed with 20ml/well 4% paraformaldehyde (Fisher, #AAJ19943K2)
for 10 minutes at room temperature. After fixation, cells were washed twice with 40ml/well PBS. Blocking was performed
with 20ml/well 5% normal goat serum (Vector Laboratories, #S-1000) in PBS for 30 minutes at room temperature. After blocking,
20ml/well monoclonal ANTI-FLAG M2-Peroxidase (HRP) antibody (Sigma-Aldrich, A8592) diluted 1/10,000 in PBS was added and
incubated for 1 hour at room temperature. This was followed by two washes with 80ml/well PBS. Then, 20ml/well SuperSignal
enzyme-linked immunosorbent assay (ELISA) Pico Chemiluminescent Substrate (Sigma-Aldrich, #37069) was added, and lumines-




5-HT2AR proteoliposomes for immunization were prepared using a receptor construct with truncated intracellular loop 3 (icl3) and
C terminus. The final construct lacking residues 278-304 and 404-471 was cloned into amodified pFastBac vector introducing a hae-
magglutinin (HA) signal sequence followed by a FLAG tag at the N terminus, and a PreScission protease site followed by a 10 3 His
tag at the C terminus.
Expression and purification of 5-HT2AR
High-titer recombinant baculovirus (> 109 viral particles per ml) was generated using the Bac-to-Bac Baculovirus Expression System
(Invitrogen, 10359016). Recombinant baculovirus was obtained by transfecting5mg of recombinant bacmid into 5x105 settled Spo-
doptera frugiperda cells (Sf9, Expression Systems, 94-001S) in a 24 well plate (Sigma-Aldrich, CLS3527) using 3ml Cellfectin II
Reagent (ThermoFisher, 10362100). After 5-12 hr, media was exchanged for 1 mL Sf-900 II SFM media (ThermoFisher, 10902096)
and incubated for 4-6 days at 27C. P0 viral stock with 109 virus particles per ml was harvested as the supernatant and used to
generate high-titer baculovirus stock by infection of 40-1000 mls of Sf9 cells and incubation for several days. Expression of
5-HT2A was carried out by infection of Sf9 cells at a cell density of 2-3 3 10
6 cells/ml in ESF921 media (Expression Systems) with
P1 virus at a MOI (multiplicity of infection) of 3-5. After 48 hr of expression at 27C in the presence of 10 mM Methiothepin
(Sigma-Aldrich, M149), cells were harvested by centrifugation, washed in PBS, and stored at 80C until use. Cells were disrupted
by thawing frozen cell pellets in a hypotonic buffer (10 mMHEPES, pH 7.5, 10 mMMgCl2, 20 mM KCl and protease inhibitors 500mM
AEBSF, 1mM E-64, 1mM Leupeptin, 150 nM Aprotinin). Membranes were purified by repeated centrifugation in a high osmolarity
buffer containing 1.0 M NaCl, 10 mM HEPES, pH 7.5, 10 mMMgCl2, 20 mM KCl, to remove soluble and membrane associated pro-
teins. Purified membranes were directly flash-frozen in liquid nitrogen and stored at 80C.
Purified membranes were resuspended in buffer containing 10 mM HEPES, pH 7.5, 10 mM MgCl2, 20 mM KCl, 150 mM NaCl,
20mM LSD (synthesized in house, see Wacker et al., 2017b), and protease inhibitors before incubating at room temperature for
1 h. After 30 min incubation in the presence of 2 mg/ml iodoacetamide (Sigma, I6125), membranes were solubilized in 10 mM HEPES, 
pH 7.5, 150 mM NaCl, 1% (w/v) n-dodecyl-b-D-maltopyranoside (DDM, Anatrace, D310), 0.2% (w/v) cholesteryl hemisuccinate 
(CHS, Sigma, C6512), 20mM LSD, and protease inhibitors for 2 h at 4C. Unsolubilized material was removed by centrifugation at 
150,000 3 g for 30 min, and 15 mM imidazole (Sigma, I5513) was added to the supernatant. Proteins were bound to TALON metal 
affinity resin (Takara, 635653) overnight at 4C using approximately 750ml resin for protein purified from 1 L of cells. The resin was then 
washed with 10 column volumes (cv) of Wash Buffer I (50 mM HEPES, pH 7.5, 800 mM NaCl, 0.1% (w/v) DDM, 0.02% (w/v) CHS, 
20 mM imidazole, 10% (v/v) glycerol, and 20mM LSD, followed by 10 cv of Wash Buffer II (25 mM HEPES, pH 7.5, 150 mM NaCl, 
0.05% (w/v) DDM, 0.01% (w/v) CHS, 10% (v/v) glycerol, and 20mM LSD). Proteins were eluted in 2.5 cv of Wash Buffer II + 
250 mM imidazole, concentrated in a 100 kDa molecular weight cut-off Vivaspin 20 concentrator (Cole-Parmer, VS2002) to 500ml, 
and imidazole was removed by desalting the protein over PD MiniTrap G-25 columns (GE Life Sciences, 28918007). The C-terminal 
10 3 His-tag was removed by addition of His-tagged PreScission protease (GenScript) and incubation overnight at 4C. Protease, 
cleaved His-tag and uncleaved protein were removed by passing the suspension through equilibrated TALON IMAC resin (Clontech) 
and collecting the flow-through. 5-HT2A /LSD complexes were then concentrated to 8.5 mg/ml with a 100 kDa molecular weight 
cut-off Vivaspin 500 centrifuge concentrator (Cole-Parmer, VS0141). Protein purity and monodispersity were tested by analytical 
size-exclusion chromatography.
100 mL of 5-HT2A concentrated to 8.5 mg/ml were mixed with 300 mL of 4 mg/ml 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC, Avanti Polar Lipids, 850355C) and cholesteryl hemi succinate (CHS) at a ratio of 9:1 (w/w) and 100 mL 5 mg/ml Lipid A (Sigma, 
L5399) both in 20 mM HEPES, pH 7.5, 100 mM NaCl, 1% (w/v) n-Octyl-b-D-Glucopyranoside (OG, Anatrace, O311). Lipids, deter-
gents, and protein were allowed to equilibrate on ice for 90 min, before rapid dilution with 1 mL of 20 mM HEPES, pH 7.5, 100 mM 
NaCl to bring OG below its critical micelle concentration. To remove detergent and form liposomes the sample was dialyzed against 
20 mM HEPES, pH 7.5, 100 mM NaCl for 24 hr, and subsequently incubated with Bio-Beads SM2 resin (BioRad, 1523920) for 4 hr.
Llama immunization was done by Capralogics using a first injection of 200 mg, followed by 5 additional injections of 100 mg of  
5-HT2A proteoliposomes.
Library Preparation
A nanobody library was generated as described previously (Pardon et al., 2014). In brief, immunized llama blood was taken to isolate 
peripheral blood lymphocytes. RNA was purified from these lymphocytes and reverse transcribed by PCR to obtain cDNA. The re-
sulting library was cloned into pTSin plasmid to a complexity of 1 3 107 colonies.
Nanobody Purification
VGS-Nb2 was subcloned from its original pCDNA3.1 destination vector after VEGAS directed evolution to pMESy4 (kindly provided 
by Jan Steyaert, Vrije Universiteit, Brussels) and purified following steps 70-73 described in the previous protocol (Pardon et al., 
2014). Nanobodies were concentrated, desalted (10 mM HEPES, 100 mM NaCl, and 10% Glycerol), and stored at 80C for future use.
Saturation and competitive radioligand binding assays
Radioligand assays were performed in parallel utilizing the same membrane preparations, binding buffer (50 mM Tris, 10 mM MgCl2, 
0.1 mM EDTA, 0.1% BSA, 0.01% ascorbic acid, pH 7.4), and purified VGS-Nb2 nanobody. For saturation assays, 5-HT2A-Gaq mem-
brane (50 mL) treated with purified VGS-Nb2 (5mM final concentration) or vehicle were added to round-bottom 96-well plates. A range 
of [N-Methyl-3H]-Lysergic Acid Diethylamide ([3H]-LSD, PerkinElmer, #NET638250UC) concentrations up to 6.80nM was added 
(25 mL) along with either vehicle (25 mL) or unlabeled 10 mM 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine HCl (25 mL, DOI HCl, 
Tocris, #2643) to determine non-specific binding. For competition assays, 5-HT2A and 5-HT2A-Gaq membranes (50mL) treated 
with purified VGS-Nb2 (7.5mM final concentration) or vehicle were added to round-bottom 96-well plates. 5-HT2A membranes 
were additionally treated with 50mM GppNHp (Abcam, ab146659) to uncouple all Ga proteins. The antagonist radioligand 
[3H]Ketanserine (PerkinElmer, #NET791025) was added (25mL) to 1nM final concentration alongside a range of unlabeled DOI con-
centrations (25mL). Plates were incubated for 1.5 hr at room temperature. Both saturation and competition binding plates were har-
vested immediately after incubation by vacuum filtration onto 0.3% polyethyleneimine pre-soaked 96-well filter mats (PerkinElmer, 
1450-421) using a 96-well Filtermate harvester, followed by three washes of cold wash buffer (50 mM Tris, pH 7.4). Solid scintillant 
(PerkinElmerm 1450-441) was melted onto dried filters and radioactivity was counted using a Wallac Trilux MicroBeta counter 
(PerkinElmer). For analysis of saturation binding data non-specific counts were removed using ‘‘Remove Baseline and Column 
Math’’ and then analyzed using ‘‘One Site – Specific Binding’’ with asymmetrical 95% confidence intervals in Graphpad Prism 
8.0. Statistics were performed as extra sum-of-squares F test (a, 0.05) for difference between best-fit values of each dataset. 
Competitive binding data was analyzed using the ‘‘One Site – Fit logIC50’’ model and compared for best fit versus a ‘‘Two sites –
Fit logIC50’’ model in Graphpad Prism 8.0 using an extra sum-of-squares F test (a, 0.05). Each dataset was then normalized to 
the ‘‘Top’’ value of the best fit model and replotted with shared parameters. Within parameter comparisons of IC50 were performed 
with an extra sum-of-squares F test (a, 0.05).
Co-Immunoprecipitation Analysis
Co-Immunoprecipitation
The FLAG-5-HT2A and FLAG-DRD2 constructs were developed from their respective TANGO plasmids with the V2Tail-TEV-tTA 
C-terminal tag removed. The mVenus-VGS-Nb2 plasmid is the same described for use in BRET experiments. The day before
transfection, HEK293T and HEK Gaq/11/sD cells were split to yield approximately 6x10
6 cells/15-cm plate next day. The following day
cells were transfected with 10 mg DNA per 15-cm; 8 mg GPCR construct and 2 mg nanobody using TransIT-2020. 6 hr after transfec-
tion media and transfection reagents were removed, cells were washed with PBS, and incubated in DMEM supplemented with 0.1%
dialyzed FBS. 48 hours after transfection the cells were washed, lysed, and FLAG-GPCR was FLAG-immunoprecipitated as
described previously (Staus et al., 2014). In brief, cells were scraped in to ice-cold lysis buffer [20 mM HEPES, 100mM NaCl,
0.5%decyl maltose-neopentyl glycol (DMNG, Anatrace, NG322)] and incubated with gentle rotation at 4C for 1 hr. Insolublematerial
was separated by centrifugation at 14,000 x g for 15 minutes at 4C. The soluble lysate was immunoprecipitated with magnetic
FLAG-M2 beads (Sigma-Aldrich, M8823), washed with TBS-M (50mM Tris HCl, 150mM NaCl, 0.5% MNG, pH 7.4), and eluted
with 3 mL of 5ug/mL 3x FLAG peptide (Sigma-Aldrich, #F4799) in TBS-M. Samples were then used immediately for downstream
applications.
Western Blot
Co-immunoprecipitated fractions taken from solubilized cell lysate (L), unbound waste (U), bead wash (W), and final elution (E) were
mixed with LDS gel loading buffer (Thermo-Fisher, #NP0007) containing 50mM fresh dithiothreitol and heated to 65C for 5 minutes.
Samples were then run on NuPage 4%–12% Bis-Tris Protein Gels (Thermo-Fisher, #NP0322) according to manufacturer’s instruc-
tions. Samples were then transferred to Immobilon PVDFmembranes for western blotting (Sigma-Aldrich, #IPSN07852) according to
manufacturer’s instructions. Protein-adhered membranes were blocked with TBS-T (50mM Tris, 150mMNaCl, 0.1% Tween 20) with
3%BSA for 1 hr followed by overnight incubation with primary antibodies to detect mVenus (Anti-GFP, rabbit, 1:1000 dilution, Novus
Biologicals, #NB600-308) and FLAG (Anti-FLAG-M2, mouse, 1:1000, Sigma-Aldrich, F1804) at 4C. The following day membranes
werewashed 43 15min in TBST and probed for 1 hr with anti-rabbit IgGHRP (1:5000, Jackson ImmunoResearch, #711-035-152) for
mVenus detection or anti-mouse IgG HRP (1:3000, Cell Signaling, #7076S) for FLAG detection. Blots were washed again 4x 15min in
TBST, mixed with Clarity Western ECL Substrate (BioRad, #1705061) and imaged on a ChemiDoc Touch Imaging System (BioRad,
#1708370).
LC-MS/MS Analysis
Immunoprecipitated samples were run on SDS-PAGE in every other lane to avoid cross contamination and bands were excised from
150kDa to 15kDa as determined by Precision Plus Protein Dual Color Standard (BioRad, #1610374). The proteins were reduced,
alkylated, and in-gel digested with trypsin overnight at 37C. Peptides were extracted and dried via vacuum centrifugation. All pep-
tide samples were stored at 80C until further analysis.
The samples were analyzed by LC/MS/MS using an Easy nLC 1200 coupled to a QExactive HFmass spectrometer (ThermoScien-
tific). Samples were injected onto an Easy Spray PepMap C18 column (75 mm id3 25 cm, 2 mm particle size) (Thermo Scientific) and
separated over a 45 min method. The gradient for separation consisted of 5%–38%mobile phase B at a 250 nl/min flow rate, where
mobile phase A was 0.1% formic acid in water and mobile phase B consisted of 0.1% formic acid in 80% acetonitrile. The QExactive
HF was operated in data-dependent mode where the 15 most intense precursors were selected for subsequent fragmentation.
Resolution for the precursor scan (m/z 350–2000) was set to 120,000 with a target value of 3 3 106 ions. MS/MS scans resolution
was set to 15,000 with a target value of 1 3 105 ions, 100 ms max IT. The normalized collision energy was set to 27% for HCD.
Dynamic exclusion was set to 30 s and precursors with unknown charge or a charge state of 1 and R 8 were excluded.
Data were searched against a Uniprot Human database (containing 22,000 protein sequences), appended with the mVenus-
VGS-Nb2 protein sequences, using Sequest within Proteome Discoverer 2.1 (Thermo Scientific). The following parameters were
used to identify tryptic peptides for protein identification: 10 ppm precursor ion mass tolerance; 0.02 Da product ion mass tolerance;
up to two missed trypsin cleavage sites. Carbamidomethylation of Cys was set as a fixed modification, and oxidation of Met and
acetylation of N terminus were set as variable modifications. Scaffold (version Scaffold_4.7.3) was used to validate MS/MS based
peptide and protein identifications. Protein/peptide identifications were accepted if they could be established at greater than
95% probability by the Scaffold Local FDR algorithm.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analysis was performed using Prism 8 (GraphPad). The specific details of each analysis type are outlined in the exper-
imental methods section, figures, and figure legends of the specific experiment. The number of biological experimental replicates per
experiment (herein, N) is outlined in each figure legend and experimental methods section.
DATA AND CODE AVAILABILITY
All graphs and data plots were generated using Prism 8 (GraphPad) unless noted otherwise herein. Alignment of tTA nucleotide se-
quences (Figure 2A) was performed and graphically rendered using Benchling (Benchling.com). Alignment of tTA peptide sequences
(Figure 2C) as well as VEGAS cloned Nb sequences (Figure S4B) was performed using T-COFFEE (Di Tommaso et al., 2011) and
graphically rendered using ESPript 3.0 (Robert and Gouet, 2014). Analysis of codon usage frequency (Figure S2D) was plotted using
Morpheus (https://software.broadinstitute.org/morpheus). The datasets for human, hamster, and Sindbis virus codon usage fre-
quency were obtained in 2018 from the Codon Usage Database (Nakamura et al., 2000). Protein structure renderings (Figures 2D
and S2B) were created using PyMol 2.2 (Schrödinger) from PDB 4AC0 (Volkers and Hinrichs, 2012) and PDB 1QPI
(Orth et al., 2000). Alignment of GPCR switch regions (Figure S3A) was performed using GPCRdb (Isberg et al., 2015; van der Kant
and Vriend, 2014; Pándy-Szekeres et al., 2018) and graphically plotted using Morpheus. Snake plots (Figure S3D) were rendered us-
ing GPCRdb. Alignment of nanobody NGS reads was graphically rendered using the Integrative Genomics Viewer (Robinson et al.,
2011; Thorvaldsdóttir et al., 2013).
Data are deposited on the Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo) under the accession number
GEO: GSE123269.
Figure S1. Sindbis Virus for Facile Directed Evolution in Mammalian Cell Culture, Related to Figure 1
(A) Epifluorescence microscope images of BHK-21 cells in culture 0, 4, 12, and 24 hr after application of pTSin-EGFP virus. (B) Mutations observed per base
measured via Illumina paired-end sequencing at each position in the EGFP transgene over time. Data are plotted as individual replicates. (C) Read distribution
from Illumina paired-end sequencing per position in the EGFP transgene over time. Data are plotted as individual replicates. (D) Insert number and size and
deletion number observed from sequencing of Sindbis packaged EGFP transgene over time. Data are plotted as individual replicates. (E) Mutations observed per
read length from sequencing of Sindbis packaged EGFP transgene over time. Data are represented individually and as linear regression, shading represents 95%
confidence band. (F) Insertions observed per read length from sequencing of Sindbis packaged EGFP transgene over time. Data are represented individually and
as linear regression, shading represents 95% confidence band. (E) Deletions observed per read length from sequencing of Sindbis packaged EGFP transgene
over time. Data are represented individually and as linear regression, shading represents 95% confidence band.
Figure S2. Directed Evolution of Transcription Factors with Sindbis, Related to Figure 2
(A) qRT-PCR quantification of Sindbis virus production from cell culture. BHK-21 cells transfected with TETO7-SSG (red) or TETO7-GFP (blue) were infected with
pTSin-tTA and treated with 1 mMDoxycycline (filled circles) or vehicle (open circles). Data are plotted as individual replications. (B) Crystal structure PDB 1QPI of
TETR in complex with TET operator DNA sequence. Residue interactions (yellow dash), waters (dot spheres), and DNA (orange) highlighted. R7 mutations
modeled in purple and annotated with residue number and mutation. (C) Codon mutation frequency of all acquired TETR sequences versus initially packaged
variants. Synonymous (blue) and nonsynonymous (red) mutations plotted at each position. (D) Codon usage frequencies (%) for wild-type tTA, R7,Homo sapiens
(human), Mesocricetus auratus (hamster), and Sindbis plotted as a heatmap. The R7-tTA (%) column summarizes the % change in usage for a particular codon
triplet between R7 and tTA. Arrows, > 10% conversion of R7 codon usage to those more frequently used in humans and hamsters.
Figure S3. VEGAS for the Evolution of GPCRs, Related to Figure 3
(A) Residue identity alignment of all human Class A GPCRs across functional domains associated with transition from inactive to active receptor conformation.
Ballesteros-Weinstein annotation of residue position was used for alignment. The receptor orphan classification (*) and conservation score (%) are listed. Red,
conserved; blue, non-conserved. (B) Transcription factor reporter primary screen for MRGPRX2 mediated (+)-Morphine response. RLuc production equates to
drug-mediated activation. Left, MRGPRX2 transfected cells. Right, empty vector transfected cells. Data are represented as mean ± SEM. (C) Snake plots of
MRGPRX2 sequence and predicted secondary structure. Mutants from each round are marked in blue, purple, and orange. The locations of the Na+ pocket (red),
ionic lock (green), PIF (yellow), and NPXXY (pink) domains are also highlighted. (D) Surface expression enzyme-linked immunosorbent assay (ELISA) to quantify
the total expression of MRGPRX2 (WT), untransfected cells (UT), and theMRGPRX2mutants obtained from VEGAS. Data are represented asmean ± SEM, N = 3.
Figure S4. VEGAS for Evolution of Active-State Nanobodies, Related to Figure 4
VEGAS was used to develop nanobodies that selectively activate diverse GPCR targets from a single cDNA library. (A–F)Transcription factor reporter primary
screen. Cells transfected with GPCRs (A,C,E) or pCDNA3.1 (B,D,F), and the indicated transcription response element (TRE) were stimulated. TRE-RLuc pro-
duction equates to drug-mediated activation of the GPCR, quantified over time. Data are represented as mean ± SEM, N = 1.
(legend on next page)
Figure S5. Positive Allosteric Modulation of GPCRs by VEGAS-Evolved Nanobodies, Related to Figure 5
VEGAS derived nanobodies were tested for direct association and allosteric modulation of their targets. (A) Bioluminescence resonance energy transfer (BRET)
association assay between GPCR-RLuc constructs and mVenus-VGS-Nb2 in the presence of increasing concentrations of 5HT. Data are represented as
mean ± SEM, N = 3.
(B) Co-immunoprecipitation determination from FLAG pull-down by western blot analysis. Loaded (L), unbound (U), washed, (W), and eluted (E) fractions an-
notated. (C) Bioluminescence resonance energy transfer (BRET) association assay between DRD2-RLuc or 5HT2A-RLuc and mVenus-VGS-Nb8 at increasing
transfection ratios of nanobody. Data are represented as mean ± SEM, N = 3 (D) Bioluminescence resonance energy transfer (BRET) association assay between
DRD2-RLuc or 5HT2A-RLuc and mVenus-VGS-Nb7 at increasing transfection ratios of nanobody. Data are represented as mean ± SEM, N = 3. (E)
Co-immunoprecipitation determination from FLAG pull-down by LC-MS/MS analysis. 5HT2A, blue; mVenus, green; VGS-Nb2, orange; DRD2, red; other pep-
tides, gray. Data are represented as total background subtracted spectral counts, N = 2. See Table S5 for raw data. (F) Calcium flux assay. Calcium mobilization
equates to relative GPCR-mediated Gaq activity. Data are represented as mean ± SEM, N = 3. (G–I) Bioluminescence resonance energy transfer (BRET) as-
sociation assay between 5HT2A-RLuc and mVenus-bArrestin-2 in the presence of increasing concentrations of DOI. (H) receptor only, (I) VGS-Nb2
co-transfected, (G) linear regression of area under the curve datasets for G, H, and additional nanobody concentrations. Data are represented as mean ± SEM,
N = 3. (J) Serum response element (SRE) reporter assay. DRD2 alone or co-transfected with 5x VGS-Nb7 or VGS-Nb8. RLuc production equates to relative
receptor activation. Data are represented as mean ± SEM, N = 2.
